Aldosterone-to-renin ratio as a screening test for primary aldosteronism - The Dutch ARRAT study

Netherlands Journal of Medicine

Volumn 66, Issue 5, 2008, Pages 220-228

  Jansen, P M ^a   Boomsma, F ^a   van den Meiracker, A H ^a   Danser, A H J ^a   Zietse, R ^a   Eijkemans, M ^a   Dees, A ^b   Berghout, A ^c   Boots, J M M ^c   Cabezas, M Castro ^d   Schrama, Y C ^d   Klessens Godfroy, F J M ^e   Carels, R A ^f   Wijbenga, J A M ^g   Groenendijk, R ^g   Hartong, S C C ^h   ten Have, S M T H ^h   Fischer, H R A ⁱ   de Bruijne, E L E ^j   Schrijver, G ^j   Deinum, J ^k   Lenders, J W M ^k   van Montfrans, G A ^l   Smulders, Y M ^m   Imholz, B P M ⁿ   Banga, J D ^o   Dijkhorst Oei, L T ^p   van den Berge, M ^q   Brouwer, R M L ^r   Woittiez, A J J ^s   Gallas, P R J ^t   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IKAZIA HOSPITAL   (Netherlands)

^c Medisch Centrum Rijnmond Zuid   (Netherlands)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

^e ROTTERDAM EYE HOSPITAL   (Netherlands)

^f Beatrix Hospital   (Netherlands)

^g Vlietland Hospital   (Netherlands)

^h Ruwaard Van Putten Hospital   (Netherlands)

ⁱ IJSSELLAND HOSPITAL   (Netherlands)

^j RED CROSS HOSPITAL   (Netherlands)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l ACADEMIC MEDICAL CENTER   (Netherlands)

^m VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ CPRLab   (Netherlands)

^o Department of Vascular Surgery   (Netherlands)

^p MEANDER MEDICAL CENTER   (Netherlands)

^q Ziekenhuis Walcheren   (Netherlands)

^r MEDISCH SPECTRUM TWENTE   (Netherlands)

^s TWENTEBORG HOSPITAL   (Netherlands)

^t Diakonessenhuis   (Netherlands)

more..

Author keywords

Aldosterone to renin ratio; Hypertension; Primary aldosteronism

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; EPLERENONE; POTASSIUM SPARING DIURETIC AGENT; RENIN;

ADD ON THERAPY; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MASS SCREENING; MULTICENTER STUDY; NETHERLANDS; PLASMA RENIN ACTIVITY; PREVALENCE; PRIMARY HYPERALDOSTERONISM; REFERENCE VALUE; SCREENING TEST;

ALDOSTERONE ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MASS SCREENING; NETHERLANDS; PREVALENCE; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SPIRONOLACTONE;

EID: 44649087034     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955;45:3-17.
2. Young WF Jr. Primary aldosteronism: management issues. Ann N Y Acad Sci 2002:970:61-76.
3. Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Int Med 1981;141:1589-93.
4. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. Clin Endocrinol Metab 2004;89:1045-50.
5. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993;20:296-8.
6. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994;21:315-8.
7. Lim PO, Dow E, Brennan C, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000;14:311-5.
8. Fardella CE, Mosso L, Gomez-Sanchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000;85:1863-7.
9. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF, Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000;85:2854-9.
10. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001;37:699-705.
11. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002;15(10 Pt 1):896-902.
12. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003;17:349-52.
13. Stowasser M, Gordon RD, Gunasekera TG, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003;21:2149-57.
14. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003;42:161-5.
15. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005;18:805-12.
16. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005;51:386-94.
17. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2293-300.
18. Williams D, Croal B, Furnace J, et al. The prevalence of a raised aldosterone-renin ratio (ARR) among new referrals to a hypertension clinic. Blood Press 2006;15:164-8.
19. Jefic D, Mohiuddin N, Alsabbagh R, Fadanelli M, Steigerwalt S. The prevalence of primary aldosteronism in diabetic patients. J Clin Hypertens 2006;8(4):253-6.
20. Williams JS, Williams GH, Raji A, et al. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens 2006;20:129-36.
21. Umpierrez GE, Cantey P, Smiley D, et al. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 2007;30:1699-703.
22. Westerdahl C, Bergenfelz A, Isaksson A, Wihl A, Nerbrand C, Valdemarsson S. High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden. Scan J Prim Health Care 2006;24:154-9.
23. Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, Mugellini A. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res 2007;30:111-7.
24. Bernini G, Moretti A, Argenio G, Salvetti A. Primary aldosteronism in normokalemic patients with adrenal incidentalomas. Eur J Endocrinol 2002;146(4):523-9.
25. Olivieri O, Ciacciarelli A, Signorelli D, et al. Aldosterone to Renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 2004;89:4221-6.
26. Hood S, Cannon J, Foo R, Brown M. Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing. Clin Med 2005;5:55-60.
27. Pizzolo F, Pavan C, Guarini P, et al. Primary hyperaldosteronism: a frequent cause of residual hypertension after successful endovascular treatment of renal artery disease. J Hypertens 2005;23:2041-7.
28. Benchetrit S, Bernheim J, Podjarny E. Normokalemic hyperaldosteronism in patients with resistant hypertension. Isr Med Assoc J 2002;4:17-20.
29. Pratt JH, Rebhun JF, Zhou L, et al. Levels of mineralocorticoids in whites and blacks. Hypertension 1999;34:315-9.
30. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40:892-6.
31. Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001;76:877-82.
32. Tiu SC, Choi CH, Shek CC, et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab 2005;90:72-8.
33. Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003;88:2489-94.
34. Gordon RD. The challenge of more robust and reproducible methodology in screening for primary aldosteronism. J Hypertens 2004;22:251-5.
35. Seiler L, Rump LC, Schulte-Monting J, et al. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 2004;150:329-37.
36. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002 Dec;40(6):897-902.
37. Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem 2002;48:1919-23.
38. Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004;22:863-9.
39. Kaplan NM. Caution about the overdiagnosis of primary aldosteronism. Mayo Clin Proc 2001;76:875-6.
40. Padfield PL. Primary aldosteronism, a common entity? the myth persists. J Hum Hypertens 2002;16:159-62.
41. Connell JM. Is there an epidemic of primary aldosteronism? J Hum Hypertens 2002;16:151-2.
42. Rossi GP, Rossi E, Pavan E, et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol 1998;49:713-23.
43. Mulatero P, Milan A, Fallo F, et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2006;91:2618-23.
44. Stowasser M, Gunasekera TG, Gordon RD. Familial varieties of primary aldosteronism. Clin Exp Pharmacol Physiol 2001;28:1087-90.
45. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-8.
46. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001;19:353-61.
47. van den Meiracker AH, Deinum J. [Primary hyperaldosteronism]. Ned Tijdschr Geneeskd 2003;147:1580-5.